Endo Pharma, Jubilant in oncology pact

U.S. based Endo Pharmaceuticals and Jubilant Biosys--a Jubilant Organosys unit--have signed a three-year pact to discover and develop oncology drugs. Under the partnership, Bangalore-based Jubilant Biosys' research will be funded by Endo Pharma. Although the financial details were not disclosed, Jubilant Biosys will also be paid for predetermined development milestones and royalties on commercialized drugs. Endo Pharma will retain ownership of any compounds produced from the collaboration and be responsible for commercialization of the drugs. Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.